Uncategorized Rho-kinase inhibitor in phase IIa study by ModernMedecine • 2012/10/03 • 0 Comments A phase IIa proof of concept study of a novel rho-kinase (ROCK) inhibitor (AMA0076, Amakem NV) is now underway in patients with glaucoma and ocular hypertension. Full Story →